RNA Clinical Trials Videos

  1. Overcoming Regulatory, Safety/Efficacy, And Toxicity Hurdles 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss what industry challenges should be top of mind for experts as it relates to the regulatory paradigm, toxicity/safety, and in vivo modeling.

  2. Adapting Clinical Strategies For Rapid Response 12/5/2024

    This presentation aims to equip sponsors, researchers, and stakeholders with the tools to enhance trial resilience and ensure continuity in today’s unpredictable global landscape.

  3. Capstan Therapeutics' CEO Laura Shawver On In Vivo Cell Engineering 11/10/2022

    Capstan Therapeutics' CEO, Laura Shawver, Ph.D., talks us through the company's in vivo CAR therapies and what led to the in vivo cell engineering breakthrough that has been decades in the making. Shawver explains the promise of harnessing mRNA and targeted LNP delivery to train a patient’s body to make CAR-T cells in vivo. She also details best practices to garner funding and investment partnership.

  4. What Have We Learned About Our LNP's Function In Vitro In 2024? 12/4/2024

    BioNTech’s Ben Muir shares a high-level overview of the LNP preclinical research advances that are the most exciting/promising today — while also reminding us of a few important caveats that accompany early-stage research. 

  5. How Is mRNA "Shaking Up" Our Regulatory Interactions & Operations Today? 5/10/2024

    The Advancing RNA Live panelists share several inconsistencies they’ve encountered working with global regulators, as well as on which aspects they’re seeing regulatory agencies applying greater scrutiny in mRNA development today.

  6. Accelerating Development In Novel & Advanced Oncology Therapies 6/15/2023

    Hear from a panel of industry experts on dissecting the shift in early-phase oncology design, focusing on Bayesian Data.

  7. What Innovations Could Help Us Overcome Preclinical Model Limitations For RNA-LNPs? 12/4/2024

    In this Advancing RNA Live clip, BioNTech’s Ben Muir and Hopewell Therapeutics’ Kate Zhang share their perspectives on the most exciting novel screening methods, innovative preclinical models, and next-gen technologies they hope can/will eventually help us bridge the translation gap between preclinical models and the clinic.

  8. A Snapshot Of The RNA Industry & Its Regulatory Progress 5/10/2024

    The experts on this Advancing RNA Live panel share their takeaways from several audience poll questions revealing which RNA molecules are getting the lion’s share of attention/development today.

  9. Q&A On LNP Cell-Specific Delivery 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.

  10. Designing Effective Multivalent mRNA Therapies: Key Regulatory Considerations 6/24/2025

    How many mRNAs are too many in a multivalent therapy? In this clip, Eliquent Life Science’s Tiffany Lucas and CureVac’s Ulrike Jägle delve into this question, emphasizing the factors that are essential for regulatory success and patient benefit.